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A gas chromatography-mass spectrometry method is presented 
which allows the simultaneous determination of the plasma 
concentrations of the selective serotonin reuptake inhibitors 
citalopram, paroxetine, sertraline, and their pharmacologically active 
N-demethylated metabolites (desmethylcitalopram, 
didesmethylcitalopram, and desmethylsertraline) after 
derivatization with the reagent N-methyl-
bis(trifluoroacetamide). No interferences from 
endogenous compounds are observed following the 
extraction of plasma samples from six different human 
subjects. The standard curves are linear over a working 
range of 10-500 ng/mL for citalopram, 10-300 ng/mL 
for desmethylcitalopram, 5-60 ng/mL for didesmethyl­
citalopram, 20-400 ng/mL for sertraline and 
desmethylsertraline, and 10-200 ng/mL for paroxetine. 
Recoveries measured at three concentrations range 
from 81 to 118% for the tertiary amines (citalopram 
and the internal standard methylmaprotiline), 73 to 
95% for the secondary amines (desmethylcitalopram, 
paroxetine and sertraline), and 39 to 66% for the 
primary amines (didesmethylcitalopram and 
desmethylsertraline). Intra- and interday coefficients of 
variation determined at three concentrations range 
from 3 to 11 % for citalopram and its metabolites, 4 to 
15% for paroxetine, and 5 to 13% for sertraline and 
desmethylsertraline. The limits of quantitation of the 
method are 2 ng/mL for citalopram and paroxetine, 
1 ng/mL for sertraline, and 0.5 ng/mL for desmethyl­
citalopram, didesmethylcitalopram, and desmethyl­
sertraline. No interferences are noted from 20 other 
psychotropic drugs. This sensitive and specific method 
can be used for single-dose pharmacokinetics. It is also 
useful for therapeutic drug monitoring of these three 
drugs and could possibly be adapted for the 
quantitation of the two other selective serotonin 
reuptake inhibitors on the market, namely fluoxetine 
and fluvoxamine. 
Introduction 
Citalopram (CIT), paroxetine (PAR), and sertraline (SER) 
(Figure 1) are new antidepressants belonging to the class of the 
selective serotonin reuptake inhibitors (SSRIs). They exhibit clin-
Figure 1 . Chemical structures of CIT, DCIT, DDCIT, PAR, SER, DSER, and MMP (internal 
standard). 
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Figure 2. The most probable fragmentation pathways of the molecular cations of CIT (A), PAR (B), SER (C), and MMP (D). 
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ical efficacy comparable to that of classical tricyclic antidepres­
sants, but they are devoid of some of the adverse anticholinergic 
and cardiovascular effects commonly associated with these 
drugs (1). In the organism, these SSRIs are biotransformed toN-
demethylated metabolites (2). Desmethylparoxetine is consid­
ered pharmacologically inactive, whereas desmethylcitalopram 
(DCIT), and perhaps also desmethylsertraline (DSER), contribute 
to the pharmacological activity of their parent drug (2). 
Although no therapeutic windows have been defined for 
SSRIs in contrast to tricyclic antidepressants, analytical 
methods for therapeutic drug monitoring of SSRIs are useful 
in several instances. They are necessary for pharmacokinetic 
experiments, but one of their major potential uses is to check 
compliance. It has been shown that up to one-third of patients 
stop taking their antidepressants after six weeks, two-thirds of 
whom do not report it to their general practitioner (3). Several 
thin-layer chromatography, high-performance liquid chro­
matography (HPLC), or gas chromatography (GC) methods 
have been published (4) for the determination of the five SSRIs 
presently on the market (CIT, PAR, SER, fluoxetine [FLX], flu-
voxamine [FLV]) and their metabolites in plasma or serum 
samples. Recently, we described a GC-mass spectrometric 
(GC-MS) method which allows the simultaneous determina­
tion of the enantiomers of FLV and either FLX or norfluoxetine 
(NFLX) after derivatization with (S)-(-)N-trifluoroacetylprolyl 
chloride (5). To our knowledge, this is the only published 
method which allows the simultaneous determination of two 
SSRIs (5). Such methods would not only decrease the cost 
and speed up analysis, but would also be useful when two 
SSRIs are administered simultaneously (4). In the present 
paper, we describe a sensitive and specific GC-MS method 
which simultaneously measures CIT, SER, PAR, and their 
N-demethylated pharmacologically active metabolites. 
Experimental 
Reagents 
CIT hydrobromide, DCIT hydrochloride, and didesmethylci­
talopram (DDCIT) L-tartrate monohydrate were supplied by 
Lundbeck (Copenhagen, Denmark). SER hydrochloride and 
Table I. Main Ions (m/z) and Relative Abundance (%) in the Mass Spectra of CIT, PAR, SER, Their N-Demethylated 
Metabolites, and MMP after Derivatization with N-Methyl-bis(trifluoroacetamide) 
CIT DCIT DDCIT PAR SER DSER MMP 
Relative Relative Relative Relative Relative Relative Relative 
abundance abundance abundance abundance abundance abundance abundance 
m/z (%) m/z (%) m/z (%) m/z (%) m/z (%) m/z (%) m/z (%) 
58 1000* 238 1000* 238 1000* 138 1000* 274 1000* 274 1000* 58 1000* 
324 31 † 58 8 69 47 425 467† 402 723† 388 52† 291 98† 
56 12 60 8 75 15 69 67 69 140 101 198 42 39 
59 39 69 44 78 14 79 41 101 273 115 149 43 17 
70 7 75 10 95 34 107 53 102 126 116 80 44 13 
71 21 78 9 109 23 109 483 110 227 127 74 45 41 
73 10 95 23 114 13 110 83 115 198 128 232 56 13 
75 6 109 18 115 19 115 50 127 227 129 161 59 38 
84 11 110 9 116 14 121 68 128 335 146 90 70 11 
86 4 114 8 123 19 122 43 129 352 159 206 71 20 
95 12 115 12 126 28 123 62 159 599 161 138 73 45 
109 9 116 10 127 9 126 38 160 293 172 144 84 29 
114 4 123 15 140 10 133 111 161 416 174 90 85 20 
115 7 140 52 154 9 135 521 202 330 202 172 165 19 
123 7 168 10 181 10 137 45 203 301 203 180 176 22 
181 4 181 8 183 50 139 107 204 185 204 174 177 11 
182 5 183 41 184 13 140 110 238 246 215 150 178 31 
183 12 184 12 190 59 146 57 239 225 238 95 189 53 
190 14 190 51 191 10 147 161 240 208 239 219 190 22 
208 27 191 9 195 12 148 37 242 128 240 87 191 55 
209 9 195 10 208 83 149 43 275 313 241 81 192 10 
218 8 208 71 209 23 151 56 276 676 246 120 201 10 
220 10 209 20 218 61 161 90 277 177 248 100 202 66 
221 9 218 52 220 63 166 298 278 127 259 85 203 72 
238 36 220 54 221 44 175 200 302 133 275 240 204 58 
239 6 221 39 222 10 192 49 386 144 276 650 205 25 
325 7 222 9 234 11 234 59 400 869 277 137 215 18 
234 9 239 170 288 183 401 947 278 113 217 13 
239 171 240 18 426 109 403 606 387 174 218 14 
240 18 374 14 404 198 389 113 292 23 
388 17 
* Base peak. 
†
 M+. 
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N-DSER maleate were obtained from Pfizer (Groton, CT). PAR 
hydrochloride was provided by SmithKline Beecham (Wor­
thing, United Kingdom). N-MMP was supplied by Novartis 
(Basel, Switzerland). N-Methyl-bis(trifluoroacetamide) was from 
Fluka (Buchs, Switzerland). Stock solutions of CIT, DCIT, and 
DDCIT were prepared using 10 ng/μL of each drug in 0.1M 
HC1, and stock solutions of PAR, SER, and DSER were pre­
pared using 100 ng/μL of each drug in 0.1M HC1. Working 
solutions were prepared using 10 and 1 ng/μL of each drug in 
0.01M HC1. Stock and working solutions of methylmaprotiline 
(MMP, internal standard) were prepared using 1 mg/mL in 
methanol and 2 ng/μL in 0.01M HC1, respectively. Working 
solutions were distributed into small aliquots and stored for up 
to 3 months at -20°C until use. All other reagents were of ana­
lytical or HPLC grade. 
Instrumentation and chromatographic conditions 
Analyses were performed on a Hewlett-Packard (Meyrin, 
Geneva, Switzerland) HP 5890 series II GC equipped with a 
splitless capillary and an electronic control pressure system. 
The GC was linked to a quadrupole HP 5972 MS operated in the 
electron impact mode. The MS conditions were as follows: ion­
izing electron energy, 50 eV; emission current, 50 μA; ion source 
temperature, approximately 180°C (heated by the interface); 
and GC-MS capillary direct interface, 280°C. Splitless injec­
tions of 3 μL were made into a fused-silica Optima 5 capillary 
column (15 m × 0.25-mm i.d., 0.25-μm film thickness) 
(Macherey-Nagel, Oensingen, Switzerland) with helium as the 
carrier gas. The column head pressure was set to maintain a con­
stant flow with a pressure of 2 psi (14 KPa). The total flow was 
50 mL/min and the septum purge was 3 mL/min. GC conditions 
Table II. Statistical Data Concerning the Analysis of CIT, PAR, SER, and Their N-Demethylated Metabolites 
CIT DCIT DDCIT PAR SER DSER 
Calibration (n = 4) 
Range (ng/mL) 10-500 10-300 5-60 10-200 20-400 20-400 
Slope: mean ± SD (CV)* 0.35 ±0.02 (5) 11.2 ±1.75 (16) 4.57 ±1.09 (24) 0.94 ±0.12 (13) 1.18 ±0.05 (4) 1.37 ±0.15 (11) 
Coefficient of correlation: mean (range) 0.998 (0.997,0.999) 0.998 (0.997,0.999) 0.991 (0.988,0.999) 0.995 (0.989,0.998) 0.999 (0.997,0.999) 0.995 (0.993,0.999) 
Recovery (n = 6) 
Concentration used (ng/mL) 20 20 10 20 30 30 
Recovery (%): mean ±SD (CV) 112 ±21 (19) 76 ±8 (10) 46 ±4 (9) 73 ±13 (18) 81 ± 7(9) 49 ±6 (12) 
Concentration used (ng/mL) 100 50 25 50 100 100 
Recovery (%): mean ± SD (CV) 118 ±16 (14) 84 ±10(12) 49 ±6 (12) 80 ±18 (22) 95 ±13 (14) 66 ±10 (15) 
Concentration used (ng/ml) 300 100 40 150 300 300 
Recovery (%): mean ±SD (CV) 91 ±15(16) 75 ±11 (14) 39 ±5 (12) 75 ±7 (10) 75 ±11 (14) 48 ±7 (14) 
Within-day variation (n = 8) 
Theoretical values (ng/mL) 20 20 10 20 30 30 
Measured values (ng/mL): mean ± SD (CV) 20.8 ±1.5 (7) 19.7 ±1.7 (9) 9.6 ±1 (10) 21.8 ±3.0 (14) 31.4 ±2.3 (7) 33.6 ± 2.6 (8) 
Percentage of theory 104 99 96 109 105 112 
Theoretical values (ng/mL) 100 50 25 50 100 100 
Measured values (ng/mL): mean ± SD (CV) 90.1 ± 2.3 (3) 45.4 ±1.7 (4) 25.5 ± 2 (8) 52.4 ±2.2 (4) 93.7 ±8.8 (9) 105 ±11.9 (11) 
Percentage of theory 90 91 102 105 94 105 
Theoretical values (ng/mL) 300 100 40 150 300 300 
Measured values (ng/mL): mean ± SD (CV) 283 ±10.8 (4) 91.9 ±5.1 (6) 40.9 ±4.1 (10) 154 ±7.7 (5) 299 ±15.1 (5) 333 ±32.5 (10) 
Percentage of theory 94 92 102 102 100 111 
Day-to-day variation (n = 7) 
Theoretical values (ng/mL) 20 20 10 20 30 30 
Measured values (ng/mL): mean ± SD (CV) 21.5 ±2.3 (11) 21.4 ±1.9 (9) 10.5 ±1.1 (10) 22.4 ±3.4 (15) 34.3 ±4.6 (13) 28.9 ±3.7 (13) 
Percentage of theory 107 107 105 112 114 96 
Theoretical values (ng/mL) 100 50 25 50 100 100 
Measured values (ng/mL): mean ± SD (CV) 89.1 ± 3.3(4) 45.6 ± 4.2 (9) 26.4 ± 2.7 (10) 48.4 ± 5.3 (11) 95.4 ± 5.5 (6) 86.2 ± 6.7 (8) 
Percentage of theory 89 91 106 97 95 86 
Theoretical values (ng/mL) 300 100 40 150 300 300 
Measured values (ng/mL): mean ± SD (CV) 284 ± 9.1 (3) 95 ± 6.5 (7) 44 ± 4.0 (9) 146 ±12.7 (9) 292 ±18.5 (6) 275 ±20.7 (8) 
Percentage of theory 94 95 111 97 97 92 
Limit of quantitation (n = 8) 
Theoretical values (ng/mL) 2 0.5 0.5 2 1 0.5 
Measured values (ng/mL): mean ± SD (CV) 2.14 ±0.36 (17) 0.53 ±0.06 (11) 0.47 ±0.07 (16) 1.94 ±0.19 (10) 0.96 ±0.06 (6) 0.47 ±0.08 (16) 
Percentage of theory 107 106 94 97 96 94 
*SD, standard deviation; CV, coefficient of variation (%). 
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were as follows: initial temperature, 160°C; initial time, 0.5 min; 
heating rate, 30°C/min until 260°C (final time 3.40 min); and 
injector temperature, 250°C. Analyses were performed in the 
selected-ion monitoring (SIM) mode with a dwell time of 50 ms 
Figure 3, SIM tracing of 1 mL blank plasma. 
for the ions at m/z 238 (DDCIT and DCIT), 274 (DSER and 
SER), 291 (MMP), 324 (CIT), and 425 (PAR). 
Extraction conditions 
To a 1-mL volume of heparinized plasma 
sample were added 100 μL of MMP (internal 
standard, 2 ng/μL), 1 mL of 1M sodium car­
bonate buffer (pH 9.4), and 6 mL of n-heptane-
ethylacetate (80:20, v/v). Extraction was per­
formed on a rotary shaker for 15 min. After cen-
trifugation (8 min, 3400 × g), the organic layer 
was transferred to another tube containing 1.2 
mL 0.1M HC1. After shaking for 15 min and cen-
trifugation, the aqueous phase was transferred 
to another tube containing 1 mL of 1M car­
bona te buffer (pH 9.4) and 150 μL of 
toluene-isoamylalcohol (85:15, v/v). After 
shaking for 15 min and centrifugation for 2 
min, the solvent was transferred to injection 
vials and evaporated to dryness under a stream 
of nitrogen at 40°C. 
Figure 4. SIM tracing of 1 mL plasma from a patient receiving 20 mg/dav CIT. CIT, ion 324, 4.68 
min; DCIT, ion 238, 5.77 min; DDCIT ion 238, 5.43 min; MMΡ, ion 291, 4.36 min. 
Derivatization conditions 
The residue was dissolved by thorough vortex 
mixing with 20 μL of N-methyl-bis(trifluoroac-
etamide) and left for 1 h at 60°C in a closed injec­
tion vial. The reagent was then evaporated to 
dryness under a stream of nitrogen at 40°C, 
reconstituted in 100 μL toluene-isoamylalcohol 
(85:15, v/v, thorough vortex mixing), and 3 μL 
was injected into the GC-MS system. 
Results and Discussion 
We recently described a GC-MS method for the 
simultaneous determination of FLV and the enan-
tiomers of FLX and NFLX with (S)-(-)N-trifluo-
roacetylprolyl chloride as the derivatizing reagent 
(5). To our knowledge, this was the first published 
method which simultaneously measured the con­
centrations of two SSRIs. We first attempted to use 
the same reagent for the three remaining SSRIs 
without success. Apparently, there was no deriva­
tization under our conditions (data not shown). 
After several trials with other reagents, we found 
that a good derivatization was obtained with 
N-methyl-bis(trifluoroacetamide). Table I lists the 
main ions in the mass spectra of CIT, SER, and 
PAR; of their N-demethylated pharmacologically 
active metabolites; and of MMP after derivatization 
with this reagent. The probable fragmentation 
pathways of the molecular cations of CIT, PAR, 
SER, and MMP are presented in Figure 2. 
It should be mentioned that FLX, NFLX, and 
FLV (the other SSRIs not analyzed by the present 
method) are also readily derivatized with 
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N-methyl-bis(trifluoroacetamide) and elute at retention times 
which are different from those of CIT, PAR, SER, and their 
metabolites (data not shown). We did not include FLX, NFLX, and 
FLV in the validation steps of the present method because we 
were more interested in separating the enantiomers of the former 
drug, which is only possible with the use of a chiral derivatizing 
reagent. However, the method described in the present paper 
could allow the simultaneous determination of the five SSRIs 
presently on the market; that is, if one is not interested in mea­
suring the enantiomers of FLX and NFLX separately. It should be 
mentioned that the present method and the method we previ­
ously described for FLX, NFLX, and FLV use the same extraction 
procedure. 
Figure 3 shows the SIM tracing of a blank plasma. Figures 
4-6 are examples of chromatograms obtained from the analysis 
of plasma samples drawn from patients receiving 20 mg/day of 
CIT, 40 mg/day of PAR, and 75 mg/day of SER, respectively. The 
Figure 5. SIM tracing of 1 mL plasma from a patient receiving 40 mg/day PAR. PAR, ion 425, 
6.39 min; MMΡ, ion 291, 4.37 min. 
Figure 6. SIM tracing of 1 mL plasma from a patient receiving 75 mg/day SER. SER, ion 274, 
5.31 min; DSER, ion 274, 4.68 min; MMP, ion 291, 4.37 min. 
Table III. Relationships between the Concentrations of CIT, DCIT, 
DDCIT as Measured by GC-MS and GC-NPD* 
GC-MS η r r 2 
CIT (ng/mL) -1.772 + 0.89(GC-NPD) 60 0.991 0.982 
DCIT (ng/mL) -3.758 + 0.988(GC-NPD) 58 0.943 0.889 
DDCIT (ng/mL) -1.462 + 1.192(GC-NPD) 37 0.917 0.841 
There are unequal numbers of samples included in the statistical analysis because results that were 
below LOQ were eliminated. 
measured concentrations of CIT, DCIT, DDCIT, PAR, SER, and 
DSER were 43,24,16,74,29, and 56 ng/mL, respectively. 
Table 2 shows a summary of the statistical data on the anal­
ysis of CIT, PAR, SER, and their metabolites. In summary, the 
mean coefficients of correlation of the calibration curves 
obtained from four separate experiments were 0.998, 0.998, 
0.991, 0.995, 0.999, and 0.995, respectively. It should be men­
tioned that no values are given for the intercepts because the 
option "force through the origin" was chosen for the calibration 
curves; with this option, better results were obtained for control 
plasma samples of low concentration (data not shown). Because 
pure standards of the derivatized compounds are not available, 
recovery was calculated by dividing the mean areas (n = 6) 
obtained after the complete extraction and derivatization pro­
cedure of plasmas containing low, medium, and high concen­
trations of the SSRIs by the mean areas obtained after direct 
derivatization of the same quantities of the pure standards. 
Recoveries were satisfactory for all compounds, 
ranging from 81 to 118% for the tertiary amines 
(CIT and MMP), from 73 to 95% for the sec­
ondary amines (DCIT, PAR, and SER), and from 
39 to 66% for the primary amines (DDCIT and 
DSER). The variability of the assays for the 
in t ra - (n = 8) and the in terday 
(n = 7) experiments measured at three concen­
trations for each substance, as assessed by the 
coefficients of variation, ranged from 3 to 11% 
for CIT and its metabolites, from 4 to 15% for 
PAR, and from 5 to 13% for SER and DSER. 
The percent theoretical concentrations, which 
represent the accuracy of the method, were all 
within ± 10% for CIT and its metabolites, within 
± 9% for PAR, and within ± 12% for SER and 
DSER. 
The limits of quantitation are defined as the 
concentrations for which the mean value of 
replicate determinations (n = 8) is within 20% of 
the actual value, the coefficient of variation less 
than 20%, and which gives a signal-to-noise 
ratio of at least 10. Limits of quantitation were 2 
ng/mL for CIT and PAR, 1 ng/mL for SER, and 
0.5 ng/mL for DCIT, DDCIT, and DSER. 
The specificity of the assay was also evaluated. 
Samples (200 ng) of each of the following 
substances diluted in methanol were dried, deriva­
tized, dried, reconstituted in 100 μL toluene-
isoamylalcohol (85:15, v/v), and injected into the 
GC-MS: amitriptyline, nortriptyline, clomipra­
mine, desmethylclomipramine, trimipramine, 
desmethyltrimipramine, maprotiline, methadone, 
mianserin, desmethylmianserin, clozapine, 
desmethylclozapine, imipramine, desmethylim-
ipramine, fluoxetine, norfluoxetine, fluvoxamine, 
procyclidine, risperidone, and 9-hydroxy risperi­
done. No interferences were noted from these 20 
psychotropic drugs. Likewise, no interferences 
were observed from endogenous compounds fol­
lowing the extraction of plasma samples from six 
and 
370 
Journal of Chromatographic Science, Vol. 36, July 1998 
different human controls who were not receiving any medication. 
It should be noted that ions of high molecular weight or molec­
ular ions were intentionally chosen in order to minimize poten­
tial interferences from other substances. Also, MMP, which was 
used as the internal standard, is not a metabolite of maprotiline 
and is not detected in patients receiving this drug (6). The sta­
bility of CIT, PAR, SER, and their metabolites was evaluated by 
analyzing spiked plasma samples stored at -20°C for different 
periods of time. No loss was noted after storage of up to 3 months. 
Finally, the stability of the derivatized forms of these three SSRIs 
with their metabolites was evaluated. No change was noted after 
storage of up to 3 days at room temperature (data not shown). 
Before the development of the present method, the concentra­
tions of CIT, DCIT, and DDCIT were measured in our laboratory 
using GC with a nitrogen-phosphorus detector (GC-NPD) after 
derivatization of the secondary and primary amines with trifluo-
roacetic anhydride (7). Sixty plasma samples which were sent to 
our laboratory for therapeutic drug monitoring of CIT using 
GC-NPD were reanalyzed using GC-MS. Table 3 shows the good 
correlations obtained between the two methods. It should be men­
tioned, however, that one value of DCIT was excluded from the sta­
tistical analysis because of a marked difference in the results 
between the two methods (142 ng/mL with GC-NPD and 30 ng/mL 
with GC-MS). We believe that the high DCIT concentration in the 
former method was caused by an unknown substance, probably a 
comedication, eluting at the same retention time. 
Conclusion 
This method, which is both sensitive and selective, allows the 
simultaneous quantification of CIT, PAR, SER, and their 
N-demethylated metabolites in plasma samples and can be used 
for single-dose pharmacokinetic studies. This procedure 
decreases the cost and time of analysis. It provides a good alter­
native analytical method for psychiatric patients who are often 
comedicated and also for patients who are medicated with two 
SSRIs (4). Finally, this method could probably be used for the 
simultaneous quantification of the five SSRIs on the market. 
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